These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 23033967)

  • 1. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
    Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
    BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Effects of Inhibitory and Stimulatory Anti-HER2 Monoclonal Antibodies on AKT/ERK Signaling Pathways.
    Soltantoyeh T; Bahadori T; Hosseini-Ghatar R; Khoshnoodi J; Roohi A; Mobini M; Golsaz-Shirazi F; Jeddi-Tehrani M; Amiri MM; Shokri F
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2255-2262. PubMed ID: 30139234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
    Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
    Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.
    Amiri MM; Golsaz-Shirazi F; Soltantoyeh T; Hosseini-Ghatar R; Bahadori T; Khoshnoodi J; Navabi SS; Farid S; Karimi-Jafari MH; Jeddi-Tehrani M; Shokri F
    Invest New Drugs; 2018 Apr; 36(2):171-186. PubMed ID: 28983766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
    Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
    Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
    Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
    Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
    Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
    Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
    Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.
    Zhang X; Chen J; Weng Z; Li Q; Zhao L; Yu N; Deng L; Xu W; Yang Y; Zhu Z; Huang H
    Mol Immunol; 2020 Mar; 119():48-58. PubMed ID: 31978707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
    Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
    Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
    Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
    Deng X; Fogh L; Lademann U; Jensen V; Stenvang J; Yang H; Brünner N; Schrohl AS
    Tumour Biol; 2013 Apr; 34(2):1161-70. PubMed ID: 23334956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
    Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
    Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
    Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
    Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.